Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 8910 participants.
Also called NCT01601704
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 8,910 participants
- Sponsor
- Orexigen Therapeutics, Inc
- Registry
-
NCT01601704 -
U1111-1162-4981
-
- Other papers using this trial's data
- Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Terminated
Technical summary
Registry record NCT01601704. Randomized; quadruple masking; primary purpose treatment. Start 2012-06 (registry gives no type); primary completion 2015-08 (actual). Results posted on 2017-02-27.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)
- Condition
- Obesity
- Condition
- Overweight
- Intervention (Drug)
- NB32
- Intervention (Drug)
- PBO
- Intervention (Behavioral)
- Weight Management Program
- Lead sponsor
- Orexigen Therapeutics, Inc
Record details
- Record id
cardio:ct-nct01601704- Content hash
c675f911d54df38328587ff57174eb2d4c494e620d2de3d23f5c451b7b469a49